No Relief from SC for Jamp India in Dispute with Jubilant Generics Over Drug Rights
Supreme Court of India
New Delhi: In a significant development in an ongoing pharmaceutical dispute, the Supreme Court of India has declined to interfere with an order of the Allahabad High Court in a case involving Jamp India Pharmaceuticals Pvt. Ltd. and Jubilant Generics Ltd., effectively allowing the High Court's directions to stand while the underlying suit continues.
The case originates from a commercial suit filed by Jubilant Generics Ltd. seeking to restrain Jamp India Pharmaceuticals and other parties from manufacturing, marketing, and distributing certain drug products, as well as from sharing confidential product dossiers with third parties. The Commercial Court, Gautam Budh Nagar, had initially granted an ad-interim injunction in August 2024 and later confirmed it in November 2024, restraining the defendants from dealing with the disputed products.
Challenging this, the petitioner (Jamp India Pharmaceuticals) argued before the High Court that the products in question were generic in nature and not subject to exclusive rights claimed by the plaintiff. The petitioner also contended that the Commercial Court failed to properly assess key legal parameters such as prima facie case, balance of convenience, and irreparable injury, and that the injunction caused significant business losses.
On the other hand, the respondent (Jubilant Generics Ltd.) sought to justify the injunction and maintain restrictions on manufacturing and use of the product dossiers, although it could not effectively defend the manner in which the Commercial Court had passed its order.
The Allahabad High Court, upon examining the matter, observed that the Commercial Court’s order was “wholly cursory” and did not record findings on essential legal requirements such as prima facie case, balance of convenience, and irreparable harm. The High Court held that such parameters are mandatory while deciding injunction applications under Order XXXIX Rules 1 and 2 of the CPC.
Accordingly, the High Court set aside the Commercial Court’s order and remanded the matter for fresh consideration, directing the lower court to decide the applications afresh within four weeks. However, it allowed the earlier ad-interim injunction to continue till the matter is re-decided.
Challenging the High Court’s decision, Jamp India Pharmaceuticals approached the Supreme Court through a Special Leave Petition.
When the matter reached the Supreme Court, the apex court observed that there was no error in the High Court’s decision and declined to interfere.
The Supreme Court disposed of the petition, effectively upholding the High Court’s remand order, while clarifying that the trial court should decide the suit independently without being influenced by prior observations. The Court also noted that related FIRs had been filed in the matter and granted liberty to the petitioner to seek appropriate legal remedies for quashing them as per law.
The case now returns to the Commercial Court for fresh adjudication, keeping the interim restrictions in place, as the legal battle between the two pharmaceutical companies continues.
To view the official orders, click the link below:
